Abstract: Decellularized xenogenic or allogenic heart valves have been used as starter matrix for tissueengineering of valve replacements with (pre-)clinical promising results. However, xenografts are associated with the risk of immunogenic reactions or disease transmission and availability of homografts is limited. Alternatively, biodegradable synthetic materials have been used to successfully create tissue-engineered heart valves (TEHV 178 words
Introduction
Worldwide, approximately 280.000 valve replacements are performed annually [1] . However, the quest for the ideal heart valve replacement is ongoing as current substitutes, like mechanical and bioprosthetic valves, lack the capability for regeneration and growth. This represents a substantial limitation for long-term durability, especially in children and young adults. Guided tissue generation and tissue engineering of heart valves are proposed to overcome the limitations of the current valve replacements. Both decellularized xenogenic and allogenic heart valves have been used as scaffold material for this purpose with preclinical and clinical trials showing promising results [2] [3] [4] [5] [6] . However, a drawback in using either xenografts or homografts is the risk for an immunogenic response [7] , which may unfavorably impact the long-term graft durability [8] . Graft decellularization is applied to decrease this immunological response, however, it is suggested that a number of inflammatory stimuli are still active within decellularized xenogenic tissue, causing graft failure [9] . In addition, the use of unfixed xenografts carries the risk of disease transmission, such as e.g. Creutzfeldt-Jakob disease [10] . The decellularized homograft (allograft) is therefore a safer option compared to the xenograft. Additionally, the homograft microstructure is favorable regarding survival, proliferation, and differentiation of reseeded cells [11] . However, a major limitation of homografts is their limited availability due to donor shortage, especially regarding small-sized valves.
As alternative to xeno-and homografts, biodegradable synthetic materials have been investigated for tissue engineering [12] [13] [14] [15] . These materials are attractive because of their unlimited supply, and the lack of any xenogenic disease transmission and rejection risk. After biodegradation of the scaffold, a completely autologous living valve can be obtained with the capability to adapt, remodel and grow [14] .These living tissue-engineered heart valves (TEHV) have shown in-vitro and in-vivo functionality [11, 14, [16] [17] [18] [19] [20] [21] [22] [23] . However, a common observation is retraction of the leaflets, resulting in valvular insufficiency [12, 19, 22, [24] [25] [26] . As the observed retraction is mainly cell-mediated, cell removal of TEHV represents a strategy to reduce retraction of the leaflets. Upon attaining sufficient amounts of extracellular matrix in-vitro, removal of the cells can be realized by a decellularization procedure.
Decellularization has been intensively investigated for xeno-and homografts [27] . Although this procedure has been applied to tissue-engineered arteries [28] [29] [30] , it is to our knowledge, not applied to TEHV. In addition to reducing cell-mediated leaflet retraction, decellularization enables storage and subsequent off-the-shelf availability of the valve replacements.
To overcome the limitations of current valve replacements and tissue-engineered solutions, there is a need for a widely available, unfixed, homologous valve substitute, without the loss of functionality due to leaflet retraction. Therefore, in this study we investigate to decellularize in-vitro grown TEHV based on rapidly degrading synthetic scaffolds and homologous cells.
We tested the feasibility of this approach by demonstrating cell removal and analysis of the biomechanical properties and in-vitro functionality. Clinical applicability was evaluated by studying the effect of storage upon the tissue properties of the decellularized TEHV. These off-the-shelf homologous valves can be used as scaffold for guided tissue generation or be reseeded prior to implantation. Non-toxicity and reseeding capacity of the decellularized TEHV with bone-marrow mesenchymal stem cells (MSC) was investigated. In addition, the impact of crimping on the reseeded cells was assessed to demonstrate feasibility of the use of reseeded decellularized TEHV for minimally invasive valve delivery.
Materials and methods

Heart valve tissue engineering
Tri-leaflet heart valve scaffolds (n=15) were fabricated from non-woven polyglycolic-acid meshes (PGA; thickness 1.0 mm; specific gravity 70 mg/cm3; Cellon, Bereldange Luxembourg) and coated with 1.75% poly-4-hydroxybutyrate (P4HB; MW: 1 x 106; TEPHA Inc., Lexington MA USA) in tetrahydrofuran (THF; Fluka (Sigma-Aldrich, St Louis MO USA)). Scaffolds were integrated into radially self-expandable nitinol stents (length=27mm, OD=25mm (n=9) or OD=30mm (n=6) when fully expanded at 37 o C; pfm-AG, Köln Germany).
Ovine vascular derived cells (previously characterized to express vimentin, SMemb, and hsp47, and partially α-SMA {Geemen, 2012 317 /id}), expanded in DMEM Advanced (Gibco, Invitrogen, Carlsbad CA USA), supplemented with 10% lamb serum (Gibco, Invitrogen), 1%
GlutaMax (Gibco, Invitrogen), and 1% Penicillin-streptomycin (Lonza, Verviers Belgium),
were seeded onto the stented heart valve scaffolds (1.5x10 6 cells/cm 2 , passage 6) using fibrin as cell carrier [13] . After seeding, scaffolds were placed into Diastolic Pulse Duplicator systems for culture in closed configuration [32] . The leaflets were exposed to dynamic strains by applying increasing transvalvular pressure differences that started from 3 mm Hg after 5 days and build up to 15 mm Hg in the 4 following days and kept as such until the fourth week. TE-medium (DMEM Advanced, supplemented with 0.1% lamb serum, 1% GlutaMax, 1% Penicillin-streptomycin, and L-ascorbic acid 2-phosphate (0.25 mg/ml; Sigma-Aldrich)) was replaced every 2 to 3 days. After 4 weeks of culturing, the TEHV were either decellularized (n=12) or analyzed directly as cell-populated controls (n=3).
Decellularization
A decellularization protocol, based on existing protocols [33, 34] , was applied to the in-vitro grown TEHV (n=12). In short, the TEHV were washed three times in PBS (Sigma-Aldrich) and decellularized overnight via incubation in PBS supplemented with 0.25% Triton X-100 (Merck, Darmstadt Germany), 0.25% sodium deoxycholate (SD, Sigma-Aldrich), and 0.02% EDTA (Sigma-Aldrich) at 37°C. Decellularization was followed by two washing cycles in PBS.
Subsequently, TEHV were treated with a nuclease digestion solution of 50-mM TRIS-HCl 
In-vitro valve performance of cell-populated-and decellularized TEHV
Functionality of the cell-populated TEHV and decellularized TEHV was visualized in a custom-built valve tester [35] , using a high-speed video camera ( 
Reseeding decellularized TEHV with mesenchymal stem cells (MSC)
MSC isolation, characterization, and differentiation potential MSC were isolated from bone marrow of adult sheep by density gradient using standardized protocols [36] . The mononuclear cell fraction was plated out in expansion medium (α-MEM (Gibco, Invitrogen), supplemented with 10% calf serum (Gibco, Invitrogen), 2 mM LGlutamin (Gibco, Invitrogen), and 1% Penicillin-streptomycin (Lonza)). After 72 hours, the non-adherent cells were discarded and adherent cells were washed gently with medium, cultured for about 14 days, and subsequently stored in liquid nitrogen. One week prior to seeding MSC were thawed and expanded further in growth medium (MSC-medium; α-mem (Gibco, Invitrogen), supplemented with 10% lamb serum (Gibco, Invitrogen), 1% GlutaMax (Gibco, Invitrogen), and 1% Penicillin-streptomycin (Lonza)), which was replaced twice per week.
Cells (passage 2 and 10) were FACS analyzed for MSC cell surface markers CD29, CD44, CD166, Stro-4, CD14, CD45, and CD31 [37] . To induce differentiation into adipocytes and osteocytes, ovine MSC were plated at 1000 cells per cm 2 in multiwall plates. For adipogenic differentiation the basic medium DMEM (Gibco, Invitrogen) was supplemented with 1 µM dexamethasone (Sigma-Aldrich), 120 µM indomethacin (Sigma-Aldrich), 10 µg/ml insulin (Sigma-Aldrich), 2 mM L-glutamine (Gibco, Invitrogen) and penicillin/streptomycin (Gibco, Invitrogen). The osteogenic induction medium contained DMEM supplemented with 10 mM β-glycerophol-2-phosphate (Sigma-Aldrich), 50µM ascorbic acid-2-phosphate (SigmaAldrich), 10µm dexamethasone, 2 mM L-glutamine, penicillin/ streptomycin and 10% FCS (Biowest, France). The chondrogenic differentiation was evaluated in a 15 ml conical tube with 2x10 5 cells/ml in DMEM medium supplemented with 2 mM L-glutamine, 1% FCS, 10 ng/ml TGF-β (Peprotech, USA), 50 µM ascorbic acid and 0.5 µg/ml insulin. During the total differentiation period of 21days all induction media were replaced three times a week. The differentiation cultures were harvested after 21 days, washed in PBS and fixed in 4%
Formalin for 1 h before histological analyses. For histological evaluation cells were stained with Oil Red-O (to detect lipid vacuoles), Alizarin Red S (to detect calcium deposits) and
Toluidin blue staining (to detect cartilage-specific proteoglycan synthesis).
Reseeding decellularized TEHV with MSC
To show feasibility of the decellularized TEHV as living implant, decellularized TEHV (n=4)
were reseeded with ovine bone marrow derived mesenchymal stem cells (MSC; 0.1x10 6 cells/cm 2 , passage 5). In order to create a confluent layer of MSC on the valves, the reseeded valves were cultured in MSC-medium under static conditions for 2 to 3 days until further analysis.
Crimping and cell viability of reseeded decellularized TEHV
To demonstrate the potential of the living TEHV for minimally invasive implantation procedures, simulation of the necessitated crimping procedure was performed with the reseeded decellularized TEHV (n=3), as described previously [22] . After simulation of the crimping procedure cell viability was assessed and compared to the non-crimped control (n=1) by whole-mount staining with cell tracker green CMFDA (CTG; Molecular Probes, the Netherlands) and propidium iodine (PI; Molecular Probes, the Netherlands), as described previously [38] . Visualization was performed with a 2-photon confocal microscope (Laser Scanning Microscope 510 META NLO, Zeiss, Germany) to observe living cells in green and dead cells in red.
Qualitative and quantitative valve tissue analyses
Histology and SEM
All TEHV (n=15) were evaluated qualitatively by histology. Representative pieces of TEHV were formalin-fixed and either embedded into paraffin and sectioned at 7 µm or snapfrozen and sectioned at 10 µm. The paraffin sections were stained with Haematoxylin and Eosin (H&E, Sigma-Aldrich) to visualize general tissue morphology and presence of cells, with Picrosirius Red for collagen structure, and with DAPI to assess the presence of cell nuclei.
Frozen sections of the cell-populated and decellularized TEHV were stained with FITClabeled phalloidin (1:200; Sigma-Aldrich) and DAPI to visualize (removal of) F-actin and nuclei, respectively. The H&E and Picrosirius Red staining were visualized by normal light microscopy. The Picrosirius Red staining was additionally visualized by polarized light microscopy. DAPI and F-actin stainings were visualized by fluorescence microscopy. Tissue samples of the reseeded decellularized TEHV were fixed in 2% glutaraldehyde (Sigma, USA)
and sputtered with platin in order to examine confluency of the seeded cells by SEM.
DNA and extracellular matrix analyses
Cell-populated (n=3), decellularized (n=4), and stored decellularized (n=2) TEHV were analyzed quantitatively for total amount of DNA, as an indicator for cell number, glycosaminoglycans, and hydroxyproline, as an indicator for collagen. For each valve, two samples per leaflet were analyzed. Hence, all valves contained 6 individual measurements, which were averaged to represent an average value for each valve. The amount of DNA was measured using the commercially available Quant-iT TM Picogreen® dsDNA kit (Molecular Probes, Invitrogen). The glycosaminoglycans content was determined using a modified version of the protocol described by Farndale et al. [39] and a standard curve prepared from chondroitin sulphate from shark cartilage (Sigma Aldrich) in addition to the samples. Briefly, 40 µl of diluted sample (without addition of chondroitin AC lyase, chondroitin ABC lyase and keratanase) was pipetted into a 96-well plate in duplicate. Subsequently, 150 µl dimethylmethylene blue (46 µM dimethylmethylene blue, 40.5 mM glycin, 40.5 mM NaCl, pH 3.0) was added and absorbance was measured at 540 nm. Hydroxyproline content was determined according to the protocol described by Huszar et al. [40] and a standard curve prepared from trans-4-hydroxyproline (Sigma Aldrich). The amounts of DNA, glycosaminoglycans, and hydroxyproline were expressed per mg dry weight of tissue.
Mechanical analyses
The mechanical properties of the leaflets of cell-populated (n=3), decellularized (n=4), and stored decellularized (n=2) TEHV were determined by uniaxial tensile tests. Three strips in the circumferential and 4 strips in the radial direction (width=2.9±0.4mm) were cut from the leaflets from each TEHV. Stress-strain curves were obtained using a uniaxial tensile tester (Kammrath & Weiss GmbH, Dortmund Germany), equipped with a 20N load cell and all samples were tested at identical strain rate (150µm/s for strips 9 mm in length and 100µm/s for strips 6 mm in length). The ultimate tensile strength (UTS), as measure for tissue strength, was defined as the maximum stress value in the stress-strain curve. The Youngs modulus, as measure for tissue stiffness, was determined as the slope in the linear region of the stress-strain curve at large strains. The obtained values for tissue strength and stiffness were averaged for each valve.
Statistics
Measurements are presented as the mean ± standard error of the mean (SEM). One-way ANOVA (post hoc Bonferroni) was used to determine the differences between the groups of valves with respect to functionality parameters, extracellular matrix contents and mechanical properties. STATGRAPHICS software (Statistical Graphics corp., USA) was used for statistical analysis with p<0.05 considered as statistically significant.
Results
Macroscopic valve appearance
The macroscopic appearance of the cell-populated TEHV revealed thin, shiny tissue formation in the wall and leaflets with no visual changes upon decellularization ( Figure 1A , D, and G). After separation of the leaflets, the cell-populated TEHV demonstrated leaflet retraction ( Figure 1B ). In the decellularized TEHV and the MSC-reseeded decellularized TEHV retraction of the leaflets was minimal ( Figure 1E and H, respectively). After exposure to pulmonary conditions in the valve tester for 20 minutes, the leaflets of the cell-populated TEHV had completely retracted ( Figure 1C ), while the decellularized leaflets did not show retraction after 24 hours of exposure to pulmonary conditions ( Figure 1F ). The crimping procedure to simulate minimally invasive valve delivery is demonstrated in Figure 1I .
In-vitro valve performance
Opening and closing behavior of the TEHV was improved after decellularization (Figure 2 ), though some prolapse of the leaflets was observed in the decellularized TEHV (Figure 2A ).
In contrast, closure of the cell-populated valve leaflets was hampered by retraction of the leaflets ( Figure 2B ). 
Qualitative and quantitative valve tissue properties
Histological appearance
Histology of the cell-populated TEHV revealed cellular tissue formation ( Figure 3A -C) with higher cellularity in the outer tissue layers, which was most clearly observed in the wall.
Abundant amounts of cross-linked collagen were detected in the leaflets ( Figure 3D and E) and the wall. After decellularization, no cells were detected ( Figure 3F-H) , while the structure and deposition of the collagen in the leaflets ( Figure 3I and J) and the wall were maintained.
Storage of the decellularized TEHV for 18 months did not affect the histological appearance (data not shown).
DNA and extracellular matrix
The results of the quantitative tissue analyses are presented in Figure 5 . Decellularization of the TEHV revealed a significant reduction (over 99%) in the amount of DNA. Although the amount of glycosaminoglycans was significantly reduced after decellularization, no differences with respect to the amount of hydroxyproline (representative for 10% of the amount of collagen [41] ) were observed. Storage of the decellularized valves did not affect tissue matrix composition. Compared to native valves, the cell-populated TEHV showed 28% of the DNA amount, 74% of collagen amount, and 94% of the amount of glycosaminoglycans measured in native ovine valve leaflets [22] .
Mechanical properties
No significant differences were observed in mechanical behavior of the strips in radial direction compared to circumferential direction in both the cell-populated and decellularized TEHV. Therefore, these values were pooled. The decellularized and stored decellularized TEHV showed a shift of the stress-strain curves to the left when compared to the cellpopulated TEHV ( Figure 5A ). The Youngs modulus of the decellularized TEHV was increased compared to the cell-populated TEHV ( Figure 5B ). The decellularization procedure did not affect tissue strength (UTS), but reduced the thickness of the TEHV ( Figure 5B ).
Storage of the decellularized TEHV for 18 months did not significantly change the mechanical properties compared to the decellularized TEHV ( Figure 5B ).
MSC characterization, differentiation, and reseeding of decellularized TEHV
The bone marrow derived population of cells exhibited an immunophenotype associated with cultured MSC (CD29+/CD44+/CD166+/ Stro-4+/CD14+-/CD45-/CD31-; data not shown).
Moreover, differentiation potential of the cells was demonstrated by differentiation into osteogenic, chondrogenic, and adipogenic cell lineages ( Figure 6A , B, and C, respectively).
After reseeding the decellularized TEHV with MSC, a confluent layer of cells was demonstrated on the leaflets and wall by histology and SEM ( Figure 6D-I ).
Viability and crimping of reseeded decellularized TEHV
The confluent cell layer was demonstrated to consist of viable cells ( Figure 7A ), which remained viable after the simulated crimping procedure ( Figure 7B ), although some spots of local damage were observed ( Figure 7B insert).
Discussion
In this study, we investigated the feasibility of a off-the-shelf tissue engineered homologous heart valve concept providing unrestricted availability and minimal risk for immunogenic reactions or disease transmission. Our approach was to decellularize in-vitro grown TEHV, based on rapidly degrading synthetic scaffolds, in order to create starter matrices for guided tissue generation and tissue engineering as an alternative to xeno-and homografts.
Complete cell removal was demonstrated histologically and biochemically. The effects of decellularization on extracellular matrix content, biomechanical properties, and in-vitro valve functionality were assessed by comparisons to cell-populated TEHV. Further, the effect of storage on the tissue properties and the reseeding feasibility of the decellularized TEHV were evaluated as well as the potential of reseeded decellularized TEHV for minimally invasive valve delivery procedures.
Cell-mediated traction is functional in ensuring the development of a desirable, highly aligned extracellular matrix in tissue-engineered cardiovascular substitutes [23, 26, 32, 42, 43] .
However, sustained traction forces can result in undesirable retraction of the leaflets, resulting in valvular regurgitation [12, 19, 22, 24, 26] . Although it has been suggested to avoid valvular insufficiency by creating longer leaflets and a larger coaptation areas [26, 44] , engineering bi-leaflet valves instead of tri-leaflet valves [23, 44] , or applying a biodegradable support material within the fibrin scaffold [19] , a sustained solution to control these traction forces is still lacking. This study shows that decellularization of the TEHV effectively reduces the retraction of the leaflets in-vitro.
The efficiency of cell removal, as well as preservation of the matrix integrity is highly dependent on the decellularization method used. Cell remnant removal is necessary, as the presence of dead cells potentially lead to inflammation and or calcification in-vivo [45] . In the present study, we choose to decellularize our TEHV with sodium deoxycholate (SD). Various studies showed that SD-based treatments are more efficient in cell removal, while maintaining matrix integrity and mechanical properties when compared to decellularization with Trypsin [8, [46] [47] [48] . The use of SD is preferred above sodium dodecylsulfate (SDS) [8, 49] and was used to produce xenogenic valve replacements that functioned properly in sheep [50] . Furthermore, an increased reseeding potential is documented for SD-treated extracellular matrix, when compared to SDS specimens [46] . The SD-treatment is often applied in combination with Triton X-100 [8, 46] , as decellularization using SD alone is not always satisfactory [50] . Therefore, we choose to include the use of Triton-X 100. The presence of small amounts of cellular antigens is described to be insufficient to elicit the type of pro-inflammatory or immune response that could adversely affect biological scaffold remodeling [51] . On the contrary, it is suggested that a low level expression of the α-galepitope has the potential to initiate an inflammatory response, leading to graft failure [9] .
When translating the approach of the current study to human, the potential inflammatory response due to expression of the α-gal-epitope is avoided by using homologous cells.
Nevertheless, with respect to calcification, complete cell removal should be pursued, as residual cells and cell remnants within the matrix might induce calcification [45] . The protocol used for decellularization of the TEHV in this study demonstrated to remove over 99% of the cellular material. Although serum nucleases can be applied to further reduce the DNA amounts in detergent pretreated tissues [29] , the clinical efficacy of commercially available materials has been claimed despite small amounts of remaining DNA [51] .
Preservation of collagen integrity in the decellularized valve replacements was demonstrated by histology. Remarkably, although not significant, biochemical analysis indicated a trend towards increased collagen amounts after decellularization, which has been observed previously by others [52] . This (non-significant) increase in collagen in the decellularized TEHV compared to the cell-populated TEHV is assumed to originate from the loss of cells and glycosaminoglycans, and therewith the relative decrease in the dry weight of the sample.
In the current study, we observed a reduction of one-third of the amount of glycosaminoglycans after decellularization. Although Grauss and colleagues [53] observed an almost complete washout of glycosaminoglycans after decellularization with Triton-X, most other studies investigating decellularization of biological matrices did not study the effect on glycosaminoglycans. Because glycosaminoglycans appear to play a significant role in shock absorption, tissue elasticity, and prevention of calcification [54] , replenishment of the lost compounds should be pursued in-vivo to enhance valvular durability. As a mature elastic network has not yet been detected in our cell-populated TEHV, the effect of decellularization on the elastin network was not explored. However, the formation of an elastic network in the TEHV is of particular importance for the biomechanical behavior of the valve [55] and is subject of current research.
The decellularized valve leaflets were thinner compared to the cell-populated leaflets, which cause is twofold. Firstly, the observed reduction of glycosaminoglycans after decellularization is likely to be associated with a loss in water content. Secondly, the cell-populated leaflets were most probably thickened due to cell-mediated retraction directly after separation of the merged leaflets. The retraction in the cell-populated leaflets may also explain the observed shift to the left of the linear part of the stress-strain curve after decellularization. Similar shifts in stress-strain curves were observed for native decellularized tissues [28] . Elongation of the cell-populated samples before testing to their original length before retraction is hypothesized to result in the same shift as observed for the decellularized samples.
Tissue strength of the leaflets was not affected by the decellularization procedure. The tissue stiffness was increased, but did not negatively affect valve functionality of the decellularized TEHV. Moreover, peak systolic pressure gradients were decreased in the decellularized TEHV, while the EOA was increased, probably due to reduced thickness of the leaflets.
Additionally, reduced leaflet retraction after decellularization had a beneficial effect on the regurgitation. Compared to the cell-populated TEHV, the decellularized TEHV showed significantly reduced regurgitation that remained stable up to 24 hours endurance testing.
Closure of the cell-populated TEHV was hampered by cell-mediated retraction of the leaflets and, therefore, endurance tests of these valves have not been performed. Although closure of the leaflets was significantly improved by decellularization, regurgitation was still observed, caused by subtle leaflet prolapse. Enlargement of the coaptation area of the leaflets is proposed to avoid the observed prolapse and is currently under investigation. The EOA and peak systolic pressure gradient of the decellularized TEHV were higher and lower, respectively, than those of the porcine aortic bioprosthesis. Though, it should be noted that the aortic bioprosthesis did not function satisfactory at pulmonary conditions.
Growth and remodeling of the valve replacement in-vivo requires a living tissue and, therewith, (re)population of the acellular tissue with cells. Still, it is unclear whether there is a need for recellularization prior to implantation, or whether circulating cells or cells from adjacent tissues may repopulate the scaffold in-vivo [56, 57] . Engineered decellularized tissues may be superior for cellular migration compared to decellularized native tissues, due to a lack of prominent elastin barriers and a less mature collagen structure [28, 52] . Longterm animal experiments have to clarify the need for in-vitro preseeding and are necessary to demonstrate growth and remodeling potential. Nevertheless, the feasibility of using decellularized TEHV as living implant was demonstrated by in-vitro reseeding with bone marrow derived mesenchymal stem cells (MSC). MSC are attractive candidates and successfully used to reseed decellularized matrices [11, 58] . Moreover, MSC show a remarkable similarity in phenotype compared to valvular interstitial cells [59] , demonstrate anti-thrombogenic [60] , and immunosuppressive properties [61] , and suitability for utilization in routine clinical practice, due to their ease of accessibility, handling and their use for multiple recipients [62] . Additionally, both the anti-thrombogenic properties of the MSC [60] and the ability to stimulate in-vivo endothelization [63] overcome the necessity of preseeding with endothelial cells.
After reseeding the decellularized TEHV, a confluent cell layer was observed within 3 days, without cell-mediated retraction of the leaflets. By reseeding the valves with MSC we aim for in-vivo recellularization with recipient cells [64] . Reseeded or not, we hypothesize that leaflet retraction of the decellularized TEHV will not re-occur in-vivo, as the contractile myofibroblasts are removed and should be replaced by cells with a more quiescent and less contractile phenotype. Moreover, in-vivo leaflet shortening has been shown to be prevented by hemodynamic loading [65] . Nevertheless, animal experiments are mandatory to elucidate whether leaflet retraction will not re-occur in-vivo.
Storage of the valves for 18 months did not affect the collagen structure, extra cellular matrix composition or the mechanical behavior. These results support the potential use of decellularized TEHV to serve as off-the-shelf valve replacements. Besides, clinical application for guided tissue generation and tissue engineering is attractive as the decellularized TEHV are suitable for minimally invasive implantation techniques. These heart valve replacement procedures represent an attractive alternative treatment option for patients with valvular heart disease and will likely have a major impact on the management of these patients over the next several years [66] . A perquisite for minimally invasive implantation techniques is crimping of the valve to fit the delivery device. In the case of a living implant, the crimping could be harmful to the cells. Therefore, simulation of the necessitated crimping procedure was evaluated for the reseeded decellularized TEHV. The observed cell damage due this crimping procedure was small and only locally. Therefore, the crimping is hypothesized not to affect the proposed in-vivo recruitment of cells by the MSC.
Conclusion
Here we demonstrate that decellularization of TEHV is feasible with efficient cell removal and preservation of collagen and tissue strength. By creating TEHV from rapid degrading synthetic scaffolds and homologous cells we avoid the risks for xenograft-specific immune responses or disease transmission. Moreover, decellularization enables on-the-shelf storage of the in-vitro grown TEHV and strongly reduces cell-mediated retraction, thereby improving valve performance. Decellularized homologous TEHV have the potential to serve as largely available off-the-shelf scaffolds without risk for xenogenic disease transmission. These scaffolds can be used as starter material for guided tissue generation and tissue engineering and potentially serve as an alternative to xeno-and homografts.
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